Rigor Reviewed

Rigor-Reviewed Manuscript

Nationwide real-world implementation of AI for cancer detection in population-based mammography screening.

Name: Αlpha¹ Rigor Record — Nationwide real-world implementation of AI for cancer detection in population-based mammography screening.
Item: Nationwide real-world implementation of AI for cancer detection in population-based mammography screening.
Rating: 96
Author: Αlpha¹

Eisemann N, Bunk S, Mukama T, Baltus H, Elsner SA, Gomille T, Hecht G, Heywang-Köbrunner S, Rathmann R, Siegmann-Luz K, Töllner T, Vomweg TW, Leibig C, Katalinic A

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 3 high issues for “Nationwide real-world implementation of AI for cancer detection in population-based mammography screening.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Observational Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
CitationsUnresolved reference ×2−0.5★
ReportingStudy design partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a large, well-conducted observational implementation study with strong reporting of methods, ethics, data/code availability, and statistical analysis. The main weakness is the non-randomized design with potential self-selection bias, which is acknowledged and partially mitigated by propensity score weighting and sensitivity analyses. Minor reporting inconsistencies (abstract vs. results numbers) and lack of a formal reporting guideline are the only copyedit-level concerns.

Both reviewers classified the study as observational, which is adopted. The evaluation covered all eight dimensions; randomization, blinding, and animal-related criteria were marked not applicable. The statistics verification checked only one reported effect estimate (consistent); other statistics were not machine-verified. The citation check flagged two references (Dryad and Zenodo DOIs) as not found in Crossref/OpenAlex, but these are data/code repositories, not typical citations, and the links are live; this is noted but not treated as a fabrication signal.

6 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple retrospective and prospective studies on AI in mammography screening, acknowledges their limitations (small sample sizes, lack of heterogeneity), and explains how PRAIM addresses these gaps. The rationale for the study is logically linked to the premise, and the hypothesis (noninferiority of AI-supported double reading) follows from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise, citing prior retrospective and prospective studies, and identifies gaps in the literature that this study addresses.

Evidence

direct quote[Introduction, paragraph 3]

“However, these studies are limited by small sample sizes (which restrict the analysis of subgroups) and by the lack of heterogeneity in terms of screening sites, mammography equipment vendors and the radiologists involved, thereby reducing their generalizability to real-world settings.”